163 related articles for article (PubMed ID: 36882990)
21. [Heart transplantation and the subsequent treatment of AL amyloidosis].
Adam Z; Krejčí J; Krejčí M; Němec P; Spinarová L; Zampachová V; Cermáková Z; Pika T; Pour L; Kořístek Z; Tomíška M; Szturz P; Král Z; Mayer J
Vnitr Lek; 2013 Feb; 59(2):136-47. PubMed ID: 23461404
[TBL] [Abstract][Full Text] [Related]
22. The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib.
Richardson PG; Laubach JP; Schlossman RL; Ghobrial IM; Redman KC; McKenney M; Warren D; Noonan K; Lunde L; Doss D; Colson K; Hideshima T; Mitsiades C; Munshi NC; Anderson KC
Eur J Haematol; 2012 May; 88(5):446-9. PubMed ID: 22300348
[TBL] [Abstract][Full Text] [Related]
23. Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial.
Landgren O; Hultcrantz M; Diamond B; Lesokhin AM; Mailankody S; Hassoun H; Tan C; Shah UA; Lu SX; Salcedo M; Werner K; Rispoli J; Caple J; Sams A; Verducci D; Jones K; Concepcion I; Ciardello A; Chansakul A; Schlossman J; Tavitian E; Shekarkhand T; Harrison A; Piacentini C; Rustad EH; Yellapantula V; Maclaughlan K; Maura F; Landau HJ; Scordo M; Chung DJ; Shah G; Lahoud OB; Thoren K; Murata K; Ramanathan L; Arcila ME; Ho C; Roshal M; Dogan A; Derkach A; Giralt SA; Korde N
JAMA Oncol; 2021 Jun; 7(6):862-868. PubMed ID: 33856405
[TBL] [Abstract][Full Text] [Related]
24. Complete remission and early relapse of refractory plasma cell leukemia after bortezomib induction and consolidation by HLA-mismatched unrelated allogeneic stem cell transplantation.
Krüger WH; Kiefer T; Schüler F; Lotze C; Busemann C; Dölken G
Onkologie; 2007 Apr; 30(4):193-5. PubMed ID: 17396042
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of VRD(Bortezomib, Lenalidomide, and Dexamethasone) Consolidation Therapy and Maintenance Therapy with Immunomodulatory Drugs(Thalidomide or Lenalidomide) after Autologous Peripheral Blood Stem Cell Transplantation in the Era of Bortezomib-Containing Induction Therapy-A Single Institution Experience.
Tanimura A; Hirai R; Nakamura M; Takeshita M; Togano T; Sekine R; Hagiwara S; Miwa A
Gan To Kagaku Ryoho; 2020 May; 47(5):789-796. PubMed ID: 32408321
[TBL] [Abstract][Full Text] [Related]
26. Assessing Pretransplant and Posttransplant Therapy Response in Multiple Myeloma Patients.
Potre C; Borsi E; Potre O; Samfireag M; Costachescu D; Cerbu B; Bratosin F; Secosan C; Negrean RA
Curr Oncol; 2022 Nov; 29(11):8501-8512. PubMed ID: 36354730
[TBL] [Abstract][Full Text] [Related]
27. [Treatment of early relapsed plasma cells leukemia after unrelated bone marrow transplant with KRD (carfilzomib, lenalidomide and dexamethasone): a case report.].
Palazzo G
Recenti Prog Med; 2020 Mar; 111(3):160-166. PubMed ID: 32157264
[TBL] [Abstract][Full Text] [Related]
28. [Lenalidomide induced therapeutic response in a patient with aggressive multi-system Langerhans cell histiocytosis resistant to 2-chloro-deoxyadenosine and early relapsing after high-dose BEAM chemotherapy with autologous peripheral blood stem cell transplantation].
Adam Z; Rehák Z; Koukalová R; Szturz P; Krejčí M; Pour L; Zahradová L; Moulis M; Kodet R; Nebeský T; Brejcha M; Adamová Z; Hájek R; Mayer J
Vnitr Lek; 2012 Jan; 58(1):62-71. PubMed ID: 22448704
[TBL] [Abstract][Full Text] [Related]
29. A case of allogeneic hematopoietic stem cell transplantation for primary plasma cell leukemia after treatment with daratumumab.
Horisawa Y; Kondo T; Hishizawa M; Yamashita K; Takaori-Kondo A
Ann Hematol; 2020 Nov; 99(11):2699-2701. PubMed ID: 32318778
[No Abstract] [Full Text] [Related]
30. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management.
Rajkumar SV
Am J Hematol; 2020 May; 95(5):548-567. PubMed ID: 32212178
[TBL] [Abstract][Full Text] [Related]
31. Retrospective Review of the Use of High-Dose Cyclophosphamide, Bortezomib, Doxorubicin, and Dexamethasone for the Treatment of Multiple Myeloma and Plasma Cell Leukemia.
Tabchi S; Nair R; Kunacheewa C; Patel KK; Lee HC; Thomas SK; Amini B; Ahmed S; Mehta RS; Bashir Q; Qazilbash MH; Weber DM; Orlowski RZ; Alexanian R; Feng L; Manasanch EE
Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):560-569. PubMed ID: 31201134
[TBL] [Abstract][Full Text] [Related]
32. Rationale and design of the German-speaking myeloma multicenter group (GMMG) trial HD6: a randomized phase III trial on the effect of elotuzumab in VRD induction/consolidation and lenalidomide maintenance in patients with newly diagnosed myeloma.
Salwender H; Bertsch U; Weisel K; Duerig J; Kunz C; Benner A; Blau IW; Raab MS; Hillengass J; Hose D; Huhn S; Hundemer M; Andrulis M; Jauch A; Seidel-Glaetzer A; Lindemann HW; Hensel M; Fronhoffs S; Martens U; Hansen T; Wattad M; Graeven U; Munder M; Fenk R; Haenel M; Scheid C; Goldschmidt H
BMC Cancer; 2019 May; 19(1):504. PubMed ID: 31138244
[TBL] [Abstract][Full Text] [Related]
33. A successful case of venetoclax-based therapy in relapsed/refractory secondary plasma cell leukemia.
Kupsh A; Arnall J; Voorhees P
J Oncol Pharm Pract; 2020 Jul; 26(5):1274-1278. PubMed ID: 31865846
[TBL] [Abstract][Full Text] [Related]
34. Successful treatment with daratumumab, lenalidomide, and dexamethasone therapy followed by autologous stem cell transplantation for newly diagnosed polyneuropathy, organomegaly, endocrinopathy, M-protein, skin changes syndrome: a case report.
Taenaka R; Shimokawa S; Katayama A; Nagao T; Obara T; Nishimura N; Tsujimoto A; Kohno K; Aoki K; Ogawa R
J Med Case Rep; 2022 Aug; 16(1):311. PubMed ID: 35978379
[TBL] [Abstract][Full Text] [Related]
35. Successful bortezomib/dexamethasone induction therapy with lenalidomide in an elderly patient with primary plasma cell leukemia complicated by renal failure and pulmonary hypertension.
Tamura S; Koyama A; Shiotani C; Kurihara T; Nishikawa A; Okamoto Y; Fujimoto T
Intern Med; 2014; 53(11):1171-5. PubMed ID: 24881743
[TBL] [Abstract][Full Text] [Related]
36. Successful treatment with bortezomib-containing regimen of primary plasma cell leukemia: a case report.
Obeidat MB; Al-Swailmeen AM; Arabeat AM; Abukamar AS
Pan Afr Med J; 2020; 36():15. PubMed ID: 32774592
[TBL] [Abstract][Full Text] [Related]
37. The efficacy and safety of modified bortezomib-lenalidomide-dexamethasone in transplant-eligible patients with newly diagnosed multiple myeloma.
Okazuka K; Ishida T; Nashimoto J; Uto Y; Sato K; Miyazaki K; Ogura M; Yoshiki Y; Abe Y; Tsukada N; Suzuki K
Eur J Haematol; 2020 Feb; 104(2):110-115. PubMed ID: 31733155
[TBL] [Abstract][Full Text] [Related]
38. Bone formation following lenalidomide-dexamethasone combination therapy in cases of multiple myeloma refractory to high-dose chemotherapy with bortezomib and autologous peripheral blood stem cell transplantation: report of a case and review of the literature.
Sekiguchi Y; Ichikawa K; Wakabayashi M; Sugimoto K; Tomita S; Izumi H; Nakamura N; Sawada T; Ohta Y; Komatsu N; Noguchi M
Int J Clin Exp Pathol; 2015; 8(8):9609-19. PubMed ID: 26464727
[TBL] [Abstract][Full Text] [Related]
39. Short Course of Post-Transplantation Cyclophosphamide and Bortezomib for Graft-versus-Host Disease Prevention after Allogeneic Peripheral Blood Stem Cell Transplantation Is Feasible and Yields Favorable Results: A Phase I Study.
Al-Homsi AS; Cole K; Bogema M; Duffner U; Williams S; Mageed A
Biol Blood Marrow Transplant; 2015 Jul; 21(7):1315-20. PubMed ID: 25765556
[TBL] [Abstract][Full Text] [Related]
40. [Treatment of AL-amyloidosis--results from one clinic and review of published experience with new agents (bortezomib, thalidomide and lenalidomide) in AL-amyloidosis].
Adam Z; Pour L; Krejcí M; Zahradová L; Krivanová A; Mardová J; Kovárová L; Stepánková S; Moulis M; Kren L; Veselý K; Svobodová I; Germáková Z; Nedbálková M; Mayer J; Hájek R
Vnitr Lek; 2010 Mar; 56(3):190-209. PubMed ID: 20394205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
